DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights. First Quarter 2023 Financial Highlights Cash position Cash, cash equivalents…

Source

Previous articleTerran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB
Next articleClearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder